An observational study in Baseline Thrombocytopenia, sponsored by Methodist Health System. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-10.
Sponsored by Methodist Health System · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 176 studies in Thrombocytopenia with a site in United States — 17 open to participants now, 20 under way, 3 of them phase 3. Thrombocytopenia · United States.
Among the 176 studies in Thrombocytopenia with a site in United States, this one is the 10th largest by planned enrollment of the 36 observational ones that give a count, is one of 5 that started in 2022, is one of 36 observational ones, reaches primary completion later than 5 of the 18 other live ones, and was the 164th registered.
483 studies on the registry are indexed under Thrombocytopenia; 101 are open to participants now.
Browse Thrombocytopenia studies →17 of the 176 studies in Thrombocytopenia with a site in United States are open now. Recruiting first, the newest first:
John Mascarenhas · Sites in United States
Ages 18+
Jiangsu HengRui Medicine Co., Ltd. · Sites in United States, Bulgaria, China and 8 more countries
Ages 18+
NICHD Neonatal Research Network · Sites in United States
Ages 1 hrs–48 hrs · Healthy volunteers
University of Colorado, Denver · Sites in United States
Ages 18–85
Weill Medical College of Cornell University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 66 Thrombocytopenia studies recruiting now, 44 (67%) set no upper age limit and 18 (27%) stop at 75 or younger; 10 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
176 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 35 · Phase 2 73 · Phase 3 31 · Phase 4 5
First in 1993; this study’s year is marked. 5 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 120 across 123 observational studies indexed under Thrombocytopenia.
Median enrollment 34 across the 135 interventional studies, 100 across the 36 observational. Of the 142 that completed or were terminated, 75 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
64 of 176 have an industry lead sponsor. The 10 most frequent:
Methodist Health System is the lead sponsor of 170 studies on the registry; 50 are open to participants now.
Methodist Health System has 1 study filed under Thrombocytopenia — fewer than ten, so there is no comparison to draw.
5 of the studies in Thrombocytopenia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06223607Methodist Health SystemDual Antiplatelet Therapy (DAPT) in Patients With Baseline Thrombocytopenia | 2026-12-28 |
| NCT06788691Weill Medical College of Cornell UniversityLuspatercept for Clonal Cytopenias of Uncertain Significance | 2027-02 |
| NCT05711485Johns Hopkins Bloomberg School of Public HealthPlatelet-Directed Whole Blood Transfusion Strategy for Malaria | 2027-04-30 |
| NCT05980806Karyopharm Therapeutics IncA Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia | 2027-06 |
| NCT06886516Rushad PatellApixaban in Thrombocytopenia | 2027-07-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 176 studies in Thrombocytopenia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The use of clopidogrel as part of DAPT will be associated with lower bleeding rates compared to ticagrelor in patients with chronic thrombocytopenia requiring Percutaneous intervention (PCI )with Drug Eluting Stent (DES) or Bare Metal Stint(BMS).
Patients with thrombocytopenia are at an increased risk of both bleeding and ischemic events following PCI; however, there is a paucity of data on how to optimally manage these risks. Data indicates that ticagrelor is associated with reduced ischemic outcomes with an accompanying increased risk of bleed in the broader population. This study will assess P2Y12 agent selection in patients with chronic thrombocytopenia to determine if one better balances risks of ischemic and bleeding events following coronary intervention
Study population of 18 years of age ,PCI with either DES or BMS during study time period (April 1, 2018 through July 1 2021) ,Thrombocytopenia on at least one occasion prior to PCI and at least one dose of DAPT post-PCI with aspirin and either clopidogrel or ticagrelor
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Incidence of bleeding
To evaluate the difference in bleeding rates in patients with chronic thrombocytopenia maintained on DAPT with clopidogrel compared to patients maintained on DAPT with ticagrelor.
Time frame: 1 year
Incidence of ischemic events
number of ischemic events
Time frame: 1 year
All-cause mortality
all-cause mortality in patients with chronic thrombocytopenia maintained on DAPT with clopidogrel compared to patients maintained on DAPT with ticagrelor.
Time frame: 1 year
Duration of DAPT
To evaluate the difference in rate of ischemic events and all-cause mortality in patients with chronic thrombocytopenia maintained on DAPT with clopidogrel compared to patients maintained on DAPT with ticagrelor.
Time frame: 1 year
Started Aug 2022 (actual). Primary completion is estimated for Dec 2026, 52 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.